Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion.
Monday's prescription for your news of note
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
As CAR-T and T-cell therapies continue to make headlines, GSK has taken up the option for Adaptimmune’s T-cell therapy.
Wednesday's shot of your news of note.
Biogen’s newly spun off hemophilia biotech Bioverativ has signed a new pact with U.K. biotech Bicycle Therapeutics.
With CAR-T therapies now reaching the market, Japanese drugmaker Takeda has made a play to grab a slice of the pie via a deal with biotech startup Noile-Immune.
Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies.
Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square.
The deal gives Jazz an option to pick up worldwide rights to two hematology antibody-drug conjugates and a third as-yet-unidentified program.
After just two years, Five Prime Therapeutics has ducked out of an immuno-oncology collaboration with InhibRx that on signing had a value of more than $460…